Lumenato™ Receives EFSA Approval, Expanding Market Availability
, May 21, 2025 /PRNewswire/ -- The European Food Safety Authority (EFSA) Panel on Nutrition, Novel Foods and Food Allergens has delivered a positive scientific opinion on Lumenato™, a standardized yellow tomato extract developed exclusively by Lycored, the global leader in natural carotenoids for food, beverage and dietary supplement products. The scientific opinion, published in the EFSA Journal, affirms the safety of Lumenato as a novel food and opens new global possibilities for brands to incorporate this unique, ingestible skincare ingredient into a variety of skin health solutions.
Derived from a proprietary breed of yellow tomato, Lumenato's active components—phytoene and phytofluene—are rare, colorless carotenoids scarcely found in nature. These compounds have a unique capacity to protect the skin from UVB radiation, the most harmful type of UV exposure. Lumenato works from the inside out to build a reservoir of goodness within the body that supports the building blocks of skin health, repair and recuperation. Backed by four pre-clinical trials and three clinical trials, Lumenato has been shown to support skin structure, both boosting and protecting collagen and influencing ceramides for improved skin barrier function, elasticity, firmness, and more. 1,2
Lumenato is available at varied concentrations in powder (starch beadlets), extract (oleoresin) and liquid emulsion delivery formats, allowing for freedom of formulation in a range of applications including nutricosmetics and derm-level care. All formats contain standardized levels of skin repairing nutrients, providing consistent results with clean-label friendly and non-GMO project verified skin support. EFSA's scientific opinion allows new global brands to start planning future product formulations using Lumenato, while awaiting the EU Novel Food list update to include yellow tomato extract.
Christiane Lippert, Global Product Manager, Beauty from Within Portfolio, states, "With this decision, Lumenato is now poised for broad acceptance across the EU, Switzerland, US, Canada, Australia, Korea, India and other countries for use in a variety of supplement products. Exclusively offered by Lycored, Lumenato is a remarkable innovation that helps achieve radiance and glow from the inside out and meets today's growing demands for nature-sourced plant based, clean-label beauty from within solutions." More information on Lumenato and supporting research is available at http://www.lycored.com/lumenato.
About Lycored
Lycored is an international company at the forefront of discovering the beauty within by combining nature's goodness with cutting edge science to deliver a sensory journey that impacts wellbeing. Established in 1995 in Israel, Lycored is the global leader in natural carotenoids for food, beverage and dietary supplement products. For more information visit www.lycored.com.
1. Tarshish et al. 2021
2. Tarshish et al. 2023
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
5 days ago
- Korea Herald
Lunit Launches Enhanced Lunit INSIGHT CXR4, Secures CE MDR Certification for Expanded AI Capabilities
Next-generation AI solution introduces new clinical features and broader disease detection for chest X-rays SEOUL, South Korea, May 28, 2025 /PRNewswire/ -- Lunit (KRX: a leading provider of AI for cancer diagnostics and therapeutics, today announced the official launch and CE certification under the Medical Device Regulation (MDR) of Lunit INSIGHT CXR4, its next-generation chest X-ray analysis solution. Lunit INSIGHT CXR4 is a comprehensive AI solution for chest imaging, designed to support radiologists across a wide range of clinical scenarios. It leverages advanced AI to detect 12 types of chest abnormalities—including lung nodules, pneumonia, and pneumothorax—expanding its diagnostic capabilities to include additional findings such as acute bone fractures. Trained on large-scale real-world datasets, the upgraded solution delivers improved diagnostic accuracy while supporting early detection of critical diseases. In addition to expanded disease detection, Lunit INSIGHT CXR4 introduces several new features designed to enhance clinical workflow and diagnostic support: With CE MDR certification, Lunit is now positioned to deploy INSIGHT CXR4 across Europe—offering enhanced diagnostic confidence and workflow efficiency for radiologists managing high imaging volumes. "With Lunit INSIGHT CXR4, we've gone beyond expanding detection—we've focused on what truly helps clinicians in their day-to-day workflow," said Brandon Suh, CEO of Lunit. "Features like active normal flagging and current-prior comparison are designed to reduce reading time and improve triage confidence, especially in high-volume settings. CE MDR certification is a key step toward broader adoption, and we're committed to bringing CXR4 to more hospitals worldwide." With CE MDR certification now in place, Lunit is preparing to pursue additional regulatory approvals to make CXR4 available in more regions. The company aims to further integrate its AI solutions into clinical workflows across diverse healthcare systems. CE MDR is the EU's enhanced regulatory standard for medical devices, ensuring stricter standards for safety, performance, and clinical validation. About Lunit Founded in 2013, Lunit (KRX: is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology —and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at
Korea Herald
7 days ago
- Korea Herald
Esaote: The new MyLab™Heron ultrasound scanner for veterinary physicians had its world premiere at the SCIVAC Rimini 2025 Congress
GENOA, Italy, May 26, 2025 /PRNewswire/ -- Esaote, a leading company in the field of medical diagnostic imaging, has presented the world premiere of the new MyLab™Heron ultrasound system at the Congress organized in Rimini from May 23 to 25 May by SCIVAC, the largest Veterinary Scientific Society in Italy, the objective of which is the scientific and professional education of veterinarians. MyLab™Heron is the latest result of Esaote's research activity in high-performance portable ultrasound systems, in which the Company has now been recognized for over 30 years and where it stands out for its comprehensive product portfolio and innovative solutions. "Veterinary physicians," stated Erminio Bassi, Esaote Vet Business Manager, "are always looking for tools that improve accuracy and efficiency, and this new ultrasound system meets these needs perfectly." MyLab™Heron is inspired by the animal from which it takes its characteristics of precision and ease of movement, even in challenging conditions, and is a portable system that combines superior performance, ease of use and mobility, including a fully cleanable touch interface. Access to all functions, from simple to advanced, is simple, intuitive and customizable, while its compact size and long-lasting battery make it ideal in any clinical setting. Workflows are designed to reduce the number of actions and to enable the veterinarian to focus on caring for the animal. Advanced technology and dedicated veterinary solutions make the diagnostic process simple and reliable. The result is faster and more accurate decisions. By analyzing real-time imaging data, artificial intelligence features built into the system reduce operator input, improving overall workflow and productivity. Similarly, MyLab™Heron offers high-resolution imaging in both superficial and deeper areas, thanks to the wide range of probes available. All this makes it possible to scan animals of any size in all applications, from general imaging to cardiology, from the musculoskeletal system to reproduction, providing unparalleled clarity. A powerful tool designed to support veterinarians working in clinics, hospitals and independently. MyLab™Heron supplements and enriches the range of Esaote ultrasound scanners dedicated to veterinary medicine, of which MyLab™Fox and MyLab™Panther are well-established, widely recognized benchmarks in international markets. They demonstrate the attention to innovation and detail with which Esaote intends to make veterinary care increasingly accessible and decisive, to improve proximity to animals and the people who love them. Esaote also supports veterinary physicians in diagnostic imaging with training programs and education, from webinars to live events; it is convinced that its vision of care based on sharing, research, and discussion with experts can help improve the future of veterinary medicine and enhance the role of the animal doctor. Esaote Group Leader in medical imaging (ultrasound, MRI, software to manage the diagnostic process). At the end of 2024, the Group had approximately 1,300 employees, half of whom in Italy. With facilities in Genoa and Florence, and its own production and research units in Italy and the Netherlands, Esaote maintains a presence in over 100 countries around the world.
Korea Herald
23-05-2025
- Korea Herald
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /PRNewswire/ -- Intalight ™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT ™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market. "Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients." DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT ™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous. "Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know." Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. "This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval." As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia. About Intalight Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT ™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at and follow us on LinkedIn and Facebook.
